Tobira Therapeutics gains $31M
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Tobira Therapeutics
|
$31M
|
Domain Associates and Frazier Healthcare Ventures |
Tobira is getting started on its development work with therapies licensed in from Japan's Takeda. |
|
Callisto Pharmaceuticals
|
$11.2M
|
RAB Special Situations (Master) Fund Limited and Absolute Octane Master Fund |
The money goes to develop Atiprimod and L-Annamcyin, which are currently in clinical trials, and Guanilib, Callistro's drug for gastrointestinal diseases. |
|
BioProcessors Corporation
|
$10M
|
LSP BioVentues |
The company provides micro-engineered solutions for biopharmaceutical process development applications for the biotechnology and pharmaceutical industries. |
|
Celator Pharmaceuticals
|
$10M
|
Associates, Quaker BioVentures, TL Ventures, Ventures West Management, GrowthWorks Capital, the Business Development Bank of Canada and Hearthstone Investment |
The funding will be used to support clinical trials as well as advance an active preclinical program. |